Faster AST results: A critical need in patient care
Antibiotic resistance is driven by the misuse and overuse of antibiotics. People are often prescribed treatments before their AST results are known, meaning they might not get the best treatment for their infection, which may worsen and increase the likelihood of antimicrobial resistance. Qualified laboratory professionals carry out hundreds of urine AST daily, it involves lots of steps and takes from 2 to 7 days to get the results and relies on manual analysis by these qualified laboratory professionals
>20%(1)
antibiotics inappropriately prescribed

40m(2)
deaths worldwide due to AMR projected by 2050

25%(3)
urine samples contain resistant bacteria
Faster Results,
Better Treatments,
Stronger Stewardship
The Astratus rapid, accurate, high throughput laboratory platform significantly reduces time to result and is less labour intensive.
It helps laboratories provide a faster, accurate antimicrobial susceptibility result enabling more targeted antimicrobial prescribing and replaces manual, labour intensive methods with one high throughput platform unlocking productivity and relieving workforce pressures
When managing urinary tract infection (UTI), the Astratus technology plays a vital role in antimicrobial stewardship and helping tackle antimicrobial resistance.
Our Solution
Same day results
- Rapid bacterial growth determination (<6 hours versus 2 to 7 days)
- Results 5x faster than existing reference methods
High throughput
- Modular design to match laboratory workload
- High throughput version up to 500 samples per shift
- Customisable compact assay cartridge to meet user needs
User Friendly
- Semi-automated testing and disposable assay cartridge
- Basic training requirement
- Reduced hands-on time
For Human, Veterinary and Research Markets
We serve human, veterinary and research markets offering a novel microcapillary “dip and test” cassette and instrument reader platform for antimicrobial susceptibility testing (AST) either direct from urine or from bacterial isolates.
As well as providing a platform for rapid AST, the technology can be used by researchers and companies developing new antimicrobials, investigating biofilms or novel therapies including phage therapies.
Contact Us
Dr Oliver HancoxChief Executive Officer
oliver.hancox@astratus.co.uk
HCR Aquis House, 49-51 Blagrave Street, Reading, Berkshire, RG1 1PL, United Kingdom
(1) Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0 (2) https://wellcome.org/news/new-forecasts-reveal-39-million-deaths-will-be-directly-attributable-bacterial-antimicrobial (3) NHS (2024) New awareness campaign to help reduce hospital admissions for urinary tract infections. Available at https://www.england.nhs.uk/2023/10/new-awareness-campaign-to-help-reduce-hospital-admissions-for-urinary-tract-%20infections/#:~:text=A%20quarter%20of%20urine%20samples,the%20most%20serious%20cases%20death